FDA Approved: SYNAGIS — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

View source ↗

Summary

The FDA approved a supplemental application for Synagis (palivizumab) filed by Swedish Orphan Biovitrum AB (publ).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Congenital Heart Disease
• Lung Disease of Prematurity
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

SUPPL AP for SYNAGIS (PALIVIZUMAB)